J&J

Showing 15 posts of 222 posts found.

FDA approves J&J’s Opsynvi for PAH treatment

March 25, 2024
Medical Communications Cardiology, FDA, J&J, Johnson & Johnson, Opsynvi, pulmonary arterial hypertension

Johnson & Johnson (J&J) has announced that the US Food and Drug Administration (FDA) has approved Opsynvi (macitentan and tadalafil) …

Johnson & Johnson acquires Ambrx Biopharma for approximately $2bn

March 11, 2024
Business Services ADCs, Ambrx Biopharma, J&J, Johnson & Johnson, Oncology, acquisition

Johnson & Johnson (J&J) has announced that it has successfully completed its acquisition of Ambrx Biopharma in an all-cash merger …

J&J’s nipocalimab gains breakthrough therapy designation from FDA for HDFN treatment

February 12, 2024
Medical Communications Breakthrough Therapy Designation, FDA, HDFN, J&J, Reproductive health

Johnson & Johnson (J&J) has announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) …

J&J’s to submit surgical robot to FDA in 2024

November 8, 2023
Research and Development FDA, J&J, Johnson & Johnson MedTech, Pharmacy, surgical robot

Johnson & Johnson MedTech have announced plans to submit the Ottava robotic surgical system to the US Food and Drug …

FDA approved Janssen’s Akeega for prostate cancer treatment

August 14, 2023
Research and Development Akeega, FDA, J&J, Janssen, Oncology, prostate cancer

The Janssen Pharmaceutical companies of Johnson & Johnson have announced that the US Food and Drug Administration (FDA) has approved …

pawel-czerwinski-2y8ol_obs1i-unsplash_2

FDA approves Talvey for the treatment of heavily pretreated multiple myeloma

August 11, 2023
Medical Communications FDA, J&J, Janssen, Oncology, Talvey, multiple myeloma

The Janssen Pharmaceutical companies of Johnson & Johnson has announced that the US Food and Drug Administration (FDA) has granted …

New warning added to J&J vaccine in US

July 13, 2021
Manufacturing and Production COVID-19, FDA, J&J, JJ, US, Vaccine

The FDA has made the decision to add a warning to the fact sheet for Johnson & Johnson’s COVID-19 vaccine, …

J&J’s Tremfya sees positive results for post-TNFi psoriatic arthritis

June 4, 2021
Medical Communications J&J, JJ

Johnson & Johnson’s interleukin-23 (IL-23) Tremfya (guselkumab) has shown positive results in Phase IIIb trials, in post-tumour necrosis factor (TNF) …

J&J COVID-19 vaccine to resume Europe rollout

April 21, 2021
Research and Development COVID-19, COVID-19 vaccine, J&J, J&J vaccine, JJ, pharma, pharma news

The Johnson & Johnson COVID-19 vaccine will continue its rollout in Europe, following a review from the EMA.

EMA launch investigation into J&J’s COVID-19 vaccine amid US blood clot reports

April 12, 2021
Sales and Marketing COVID-19, EMA, J&J, JJ, Vaccine

The EMA is reviewing reports of rare blood clots in four people in the US who received Johnson & Johnson’s …

shutterstock_159488225

Renewed BARDA backing boosts J&J’s COVID-19 vaccine funding by $1bn

November 17, 2020
Manufacturing and Production, Research and Development BARDA, COVID-19, J&J, JJ, Janssen, Vaccine

Johnson & Johnson has said that it is injecting around $1 billion of funding into its research efforts to develop …

J&J launches second global COVID-19 vaccine trial, evaluating two-dose regimen

November 16, 2020
Research and Development, Sales and Marketing COVID-19, J&J, JJ, Janssen, Vaccine

Johnson & Johnson has kicked off a second global Phase 3 trial to assess the safety and efficacy of its …

J&J’s appeal shot down over $2.12m payment due to allegedly carcinogenic talc products

November 4, 2020
Research and Development, Sales and Marketing J&J, JJ, baby powder, ovarian cancer, talc

Johnson & Johnson has suffered a legal defeat in its ongoing dispute with consumers over damages relating to use of …

shutterstock_512649

Johnson & Johnson to contribute a further $1 billion to US opioid settlement

October 14, 2020
Research and Development, Sales and Marketing J&J, JJ, opioid crisis, opioids, pharma

Johnson & Johnson will pay another $1 billion to settle lawsuits alleging it fuelled the opioid crisis in the US. …

J&J halts COVID-19 vaccine study following unidentified participant illness

October 13, 2020
Manufacturing and Production, Research and Development COVID-19, J&J, JJ, Vaccine, pharma

Johnson & Johnson has announced its decision to slam the brakes on the development programme for its COVID-19 vaccine following …

Latest content